Envoy Medical raises $30 million, nears completion of cochlear implant trial
Published: 23 Mar 2026
Author: Precedence Research
The hearing health company announced Envoy Medical Inc has secured $30 million in an upsized public offering with potential for an additional $48 million through milestone-linked warrants. The microcap company is valued at approximately $58 million, has seen its stock surge 44% over the past week, trading at $0.76.
Funding round led by new investor Nantahala Capital and shareholder Glen Taylor, with participation from healthcare funds including Broadfin Holdings and existing investors, including board members and management. InvestingPro data shows the company is burning through cash with short term obligation and exceed liquid assets reflecting in its current ratio of 0.64. This results in capital infusion, which comes in critical time.
Lucas added that we remain encouraged by what we are hearing from the trial and look forward to sharing more as results are formally analysed and published. We expect to provide an update at an industry meeting as we continue advancing toward the goal of redefining the standard of care with a fully implanted cochlear implant."
According to Towards Healthcare, the Cochlear Implant Market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 2.54 billion in 2026 to approximately USD 5.77 billion by 2035, representing a compound annual growth rate (CAGR) of 9.54% from 2026 to 2035. This market is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
The Acclaim cochlear implant
The cochlear implant called Acclaim has fully implanted 47 of the planned 56 participants in its pivotal clinical trial, with 9 participants scheduled for surgery. Despite its innovative technology company generated $0.21 million in revenue over the last twelve months. It uses a sensor designed to leverage the ear’s natural anatomy instead of an external microphone.
The FDA has approved a fully implanted active middle ear implant for moderate to severe sensorineural hearing loss. Also uses a sensor designed to leverage the ear’s natural anatomy instead of an external microphone to capture sound using Envoy Medical's proprietary implanted piezoelectric sensor technology.
Chief Executive Officer of Envoy Medical, Brent Lucas, said, " This financing has the potential to not only fund the Company through our pivotal clinical trial and regulatory submission, but also through initial commercialisation.”
A recent report by Towards Healthcare, Cochlear Implant Market, aims to improve the signal-to-noise ratio in cochlear implant systems by amplifying acoustic signals at the input source. These developments mark significant progress for Envoy Medical in advancing its cochlear implant solutions.